OPTIMIZING THE EXTENT OF SURGERY AFTER NEOADJUVANT THERAPY IN LOCALLY ADVANCED BREAST CANCER: CLINICAL OUTCOMES AND EVIDENCE-BASED SURGICAL DECISION-MAKING
Keywords:
locally advanced breast cancer; neoadjuvant therapy; breast-conserving surgery; mastectomy; axillary surgery; pathological response; locoregional recurrence; overall survival.Abstract
Background: Optimizing surgical extent after neoadjuvant systemic therapy (NST) in locally advanced breast cancer requires balancing adequate locoregional control against treatment-related morbidity and functional outcomes. Objective: To critically examine surgical de-escalation and oncological endpoints using a supplied regional clinical report alongside evidence from major randomized trials and meta-analyses. Methods: A descriptive appraisal of an author-supplied retrospective/prospective cohort summary (84 women, 2023–2025) was integrated with a focused narrative synthesis of published evidence. The cohort’s aggregated values were not independently verified; no patient-level reanalysis was possible. Results: The source report described 44 patients managed with neoadjuvant multimodality therapy and 40 comparison patients; reported local recurrence proportions were 9.1% and 22.5%, respectively, and reported three-year overall survival was 68.2% and 47.5%. These unadjusted findings cannot establish a treatment effect because stage, molecular subtype, follow-up, and treatment selection were not controlled. Published evidence supports increased breast conservation after NST, but also underscores the importance of localization, margin assessment, radiation, and systemic therapy tailored to tumor biology. Conclusions: Surgical extent should be determined by residual disease distribution, feasibility of negative margins, nodal response, and multidisciplinary planning rather than tumor shrinkage alone. Prospective standardized outcome assessment is required to validate regional findings.
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660.
2. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288–300. doi:10.1001/jama.2018.19323.
3. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–1220. doi:10.1093/annonc/mdz173.
4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39. doi:10.1016/S1470-2045(17)30777-5.
5. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi:10.1016/S0140-6736(13)62422-8.
6. Schmid P, Cortes J, Dent R, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981–1991. doi:10.1056/NEJMoa2409932.
7. Geyer CE Jr, Untch M, Huang CS, et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025;392:249–257. doi:10.1056/NEJMoa2406070.
8. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2026;394:845–857. doi:10.1056/NEJMoa2514661.
9. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–785. doi:10.1200/JCO.2007.15.0235.
10. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere). Lancet Oncol. 2012;13(1):25–32. doi:10.1016/S1470-2045(11)70336-9.
11. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628. doi:10.1056/NEJMoa1814017.
12. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–2159. doi:10.1056/NEJMoa1612645.
13. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 clinical trial. JAMA. 2013;310(14):1455–1461. doi:10.1001/jama.2013.278932.
14. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. doi:10.1016/S1470-2045(14)70460-7.
